Cognition Therapeutics Inc (CGTX) - Total Assets
Based on the latest financial reports, Cognition Therapeutics Inc (CGTX) holds total assets worth $43.40 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Cognition Therapeutics Inc (CGTX) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Cognition Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Cognition Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Cognition Therapeutics Inc book value and equity for net asset value and shareholders' equity analysis.
Cognition Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cognition Therapeutics Inc's total assets of $43.40 Million consist of 97.8% current assets and 2.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 82.7% |
| Accounts Receivable | $2.69 Million | 8.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Cognition Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Cognition Therapeutics Inc (CGTX) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cognition Therapeutics Inc's current assets represent 97.8% of total assets in 2024, an increase from 96.0% in 2019.
- Cash Position: Cash and equivalents constituted 82.7% of total assets in 2024, up from 38.8% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 8.9% of total assets.
Cognition Therapeutics Inc Competitors by Total Assets
Key competitors of Cognition Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Cognition Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.44 | 2.11 | 2.13 |
| Quick Ratio | 6.44 | 2.11 | 1.96 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $36.23 Million | $14.12 Million | $3.66 Million |
Cognition Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Cognition Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.08 |
| Latest Market Cap to Assets Ratio | 2.60 |
| Asset Growth Rate (YoY) | -14.0% |
| Total Assets | $30.23 Million |
| Market Capitalization | $78.56 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cognition Therapeutics Inc's assets at a significant premium (2.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Cognition Therapeutics Inc's assets decreased by 14.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cognition Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Cognition Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $30.23 Million | -14.02% |
| 2023-12-31 | $35.16 Million | -30.27% |
| 2022-12-31 | $50.42 Million | -14.73% |
| 2021-12-31 | $59.14 Million | +730.69% |
| 2020-12-31 | $7.12 Million | -4.56% |
| 2019-12-31 | $7.46 Million | -- |
About Cognition Therapeutics Inc
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2… Read more